Von Willebrand Factor-Specific Antibodies Developing upon Treatment of FVIII-Deficient Mice with Different FVIII Preparations

Publisher： Karger

E-ISSN： 1421-9662|119|4|244-247

ISSN： 0001-5792

Source： Acta Haematologica, Vol.119, Iss.4, 2008-07, pp. : 244-247

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The important role of von Willebrand factor in platelet‐derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 7, 2015-07 ,pp. : 1301-1309

John Wiley & Sons Inc

Access to resources Recommend Favorite

Is some better than none: are TEG and TGA profiles different in severe FVIII‐deficient patients with inhibitors?

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 398-404

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 837-845

John Wiley & Sons Inc

Access to resources Recommend Favorite

Kogenate®® FS: antihemophilic factor rFVIII-FS

By Lusher Jeanne   Chitlur Meera  

Therapy, Vol. 3, Iss. 6, 2006-11 ,pp. : 699-708

Future Medicine

Access to resources Recommend Favorite

Switching from current factor VIII (FVIII) to longer acting FVIII concentrates – what is the real potential benefit?

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 297-299

John Wiley & Sons Inc

Access to resources Recommend Favorite